| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Angiotensin II type 1 (AT1) receptor. Angiotensin II (5-8) binds to the AT1 receptor, a G protein-coupled receptor, stimulating signaling in vascular smooth muscle cells and increasing intracellular calcium levels. It may also bind to other angiotensin binding sites.
|
|---|---|
| ln Vitro |
Angiotensin II (5-8) binds to the AT1 receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca2+ levels. As a C-terminal fragment of angiotensin II, it retains some of the receptor-binding properties of the full-length peptide. It is used to study angiotensin-related signaling pathways.
|
| ln Vivo |
No specific in vivo activity data is available for Angiotensin II (5-8). As a peptide fragment, it may have vasoconstrictor activity similar to the full-length angiotensin II peptide, though its potency may be reduced. It is used in research to study the renin-angiotensin system and cardiovascular function.
|
| Enzyme Assay |
In vitro receptor binding assays for Angiotensin II (5-8) typically involve radioligand displacement using membrane preparations from cells expressing the AT1 receptor. The peptide's ability to stimulate calcium mobilization in vascular smooth muscle cells can be measured using fluorescent calcium indicators. Selectivity can be assessed by testing against AT2 receptors.
|
| Cell Assay |
The in vitro cellular activity of Angiotensin II (5-8) is evaluated in vascular smooth muscle cells expressing AT1 receptors. Cells are treated with the peptide, and intracellular calcium levels are measured using fluorescent dyes. Downstream signaling (e.g., MAPK activation) can also be assessed. The peptide's effects on cell contraction or proliferation may be studied.
|
| Animal Protocol |
In vivo animal studies with Angiotensin II (5-8) would typically involve administration to rodents via intravenous injection or infusion to study cardiovascular effects. Blood pressure, heart rate, and renal function would be monitored. The peptide could also be used in models of hypertension or cardiovascular disease to study the renin-angiotensin system.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for Angiotensin II (5-8). As a peptide (molecular weight 512.6, formula C26H36N6O5), it is expected to have poor oral bioavailability and rapid degradation in vivo. The peptide is typically administered via injection for in vivo studies. Stability may be limited due to susceptibility to proteolytic degradation.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for Angiotensin II (5-8). As a research peptide intended for laboratory use, standard safety precautions should be observed. No clinical toxicity studies have been reported. The peptide has not been evaluated for genotoxicity, carcinogenicity, or reproductive toxicity.
|
| References |
|
| Additional Infomation |
Angiotensin (5-8) is a dichlorobenzene.
Angiotensin II (5-8), human is an endogenous C-terminal fragment of angiotensin II that binds to the AT1 receptor. It stimulates GPCRs in vascular smooth muscle cells and increases intracellular calcium. It is a research tool for studying the renin-angiotensin system in cardiovascular and renal research. It is not approved for clinical use. |
| Molecular Formula |
C26H36N6O5
|
|---|---|
| Molecular Weight |
512.60124
|
| Exact Mass |
512.275
|
| CAS # |
34233-50-6
|
| PubChem CID |
9806448
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.932
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
37
|
| Complexity |
804
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N
|
| InChi Key |
RXGAHIIILDHXJU-XSXWSVAESA-N
|
| InChi Code |
InChI=1S/C26H36N6O5/c1-3-16(2)22(27)24(34)30-19(13-18-14-28-15-29-18)25(35)32-11-7-10-21(32)23(33)31-20(26(36)37)12-17-8-5-4-6-9-17/h4-6,8-9,14-16,19-22H,3,7,10-13,27H2,1-2H3,(H,28,29)(H,30,34)(H,31,33)(H,36,37)/t16-,19-,20-,21-,22-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 65 mg/mL (~126.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9508 mL | 9.7542 mL | 19.5084 mL | |
| 5 mM | 0.3902 mL | 1.9508 mL | 3.9017 mL | |
| 10 mM | 0.1951 mL | 0.9754 mL | 1.9508 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
